An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo
Craig Cherrin(United States Military Academy), Hans E. Huber(Health Strat (Kenya)), Karen Leander(United States Military Academy), E. Mahan, Kathleen Haskell(Upsher-Smith Laboratories (United Kingdom)), Thomayant Prueksaritanont(United States Military Academy), George D. Hartman(Joint BioEnergy Institute), J. M. HOFFMAN, Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Mark T. Bilodeau(Kettering University), Neal Rosen(Memorial Sloan Kettering Cancer Center), Bonnie J. Howell(Johns Hopkins University), Philip E.J. Sanderson, Qing‐Bai She(University of Kentucky), Deborah Defeo-Jones, Raymond C. F. Jones(University of Washington), Aubrey Watkins, R. Robinson(United States Military Academy), Guoqiang Jiang(Salk Institute for Biological Studies)
Cited by 59
Related Papers
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
|Cancer Research|2006|2.5k
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
|Science|1993|2.3k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k